World's Best Scientists 2026 revealed!
Award Badge
Best Scientists
2025
Award Badge
Medicine
Greece
2026

D-Index & Metrics

Best Scientists

D-Index
170
Citations
133797
World Ranking
864
National Ranking
3

Medicine

D-Index
173
Citations
142476
World Ranking
467
National Ranking
3

Research.com Recognitions

  • 2026 - Research.com Medicine in Greece Leader Award
  • 2025 - Research.com Best Scientists Award
  • 2025 - Research.com Medicine in Greece Leader Award
  • 2023 - Research.com Medicine in Greece Leader Award
  • 2022 - Research.com Medicine in Greece Leader Award

Overview

Meletios A. Dimopoulos is affiliated with the National and Kapodistrian University of Athens in Greece. Their work spans multiple areas within medicine and biochemistry, genetics, and molecular biology, with a particular focus on hematology and oncology.

The scientist's main fields of study include:

  • Medicine
  • Biochemistry, Genetics and Molecular Biology

Subfields of focus encompass:

  • Hematology
  • Molecular Biology
  • Oncology
  • Infectious Diseases
  • Genetics

Key topics explored in their research are diverse, reflecting an emphasis on hematological disorders and related therapeutic approaches:

  • Multiple Myeloma Research and Treatments
  • Protein Degradation and Inhibitors
  • Peptidase Inhibition and Analysis
  • Chronic Lymphocytic Leukemia Research
  • SARS-CoV-2 and COVID-19 Research
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • COVID-19 Clinical Research Studies

Frequent publication venues for their work highlight a presence in well-regarded journals within hematology and oncology:

  • Blood
  • Journal of Clinical Oncology
  • Clinical Lymphoma Myeloma & Leukemia
  • American Journal of Hematology
  • HemaSphere

They have collaborated extensively with several coauthors, showing recurring professional partnerships:

  • Evangelos Terpos
  • Efstathios Kastritis
  • Maria Gavriatopoulou
  • Ioannis Ntanasis-Stathopoulos
  • Despina Fotiou

Notable recent papers include:

  • Hematological findings and complications of COVID-19, 2020, American Journal of Hematology
  • Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, 2021, Annals of Oncology
  • Daratumumab-Based Treatment for Immunoglobulin Light-Chain Amyloidosis, 2021, New England Journal of Medicine
  • Organ-specific manifestations of COVID-19 infection, 2020, Clinical and Experimental Medicine
  • A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study, 2020, Blood

Best Publications

  • International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.

    S. Vincent Rajkumar;Meletios A. Dimopoulos;Antonio Palumbo;Joan Blade

  • International uniform response criteria for multiple myeloma

    B. G. M. Durie;J.-L. Harousseau;J. S. Miguel;J. Blade

  • Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group

    Robert A. Kyle;J. Anthony Child;Kenneth Anderson;Bart Barlogie

  • International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

    Shaji Kumar;Bruno Paiva;Kenneth C. Anderson;Brian Durie

  • Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

    Jesús F. San Miguel;Rudolf Schlag;Nuriet K. Khuageva;Meletios A. Dimopoulos

  • Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

    Antonio Palumbo;Hervé Avet-Loiseau;Stefania Oliva;Henk M. Lokhorst

  • Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma

    Meletios Dimopoulos;Andrew Spencer;Michael Attal;H. Miles Prince

  • Hematological findings and complications of COVID-19.

    Evangelos Terpos;Ioannis Ntanasis-Stathopoulos;Ismail Elalamy;Efstathios Kastritis

  • Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

    Meletios A. Dimopoulos;Albert Oriol;Hareth Nahi;Jesus San-Miguel

  • Osteonecrosis of the Jaw in Cancer After Treatment With Bisphosphonates: Incidence and Risk Factors

    Aristotle Bamias;Efstathios Kastritis;Christina Bamia;Lia A. Moulopoulos

  • Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

    Abstr Act;Sagar Lonial;Meletios Dimopoulos;Antonio Palumbo

  • Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

    James R. Berenson;Alan Lichtenstein;Lester Porter;Meletios A. Dimopoulos

  • Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

    S. Vincent Rajkumar;Jean Luc Harousseau;Brian Durie;Kenneth C. Anderson

  • Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia

    Roger G. Owen;Steven P. Treon;Ayad Al-Katib;Rafael Fonseca

  • Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

    A. Palumbo;S. V. Rajkumar;M. A. Dimopoulos;P. G. Richardson

  • Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

    Jesús F. San-Miguel;Vânia T.M. Hungria;Sung Soo Yoon;Meral Beksac

  • Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

    Jesús Fernando San Miguel;Jesús Fernando San Miguel;Katja Weisel;Philippe Moreau;Martha Lacy

  • Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

    Meletios Athanasios Dimopoulos;Philippe Moreau;Antonio Palumbo;Douglas Edgar Joshua

  • International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders

    A. Dispenzieri;R. Kyle;G. Merlini;J. S. Miguel

  • Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

    R A Kyle;B G M Durie;S V Rajkumar;O Landgren

Frequent Co-Authors

Evangelos Terpos
Evangelos Terpos National and Kapodistrian University of Athens
Efstathios Kastritis
Efstathios Kastritis National and Kapodistrian University of Athens
Michele Cavo
Michele Cavo University of Bologna
Paul G. Richardson
Paul G. Richardson Harvard University
Antonio Palumbo
Antonio Palumbo University of Turin
Roman Hájek
Roman Hájek University of Ostrava
Philippe Moreau
Philippe Moreau University of Nantes
Maria-Victoria Mateos
Maria-Victoria Mateos University of Salamanca
Pieter Sonneveld
Pieter Sonneveld Erasmus University Rotterdam
Heinz Ludwig
Heinz Ludwig University of Vienna

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in medical careers beyond becoming a physician, there are many online degree options in healthcare. Online programs are a flexible way to advance your qualifications while accommodating work and family commitments.

If you are considering a leadership role in healthcare, exploring top online mha programs that are cahme accredited ensures you receive a high-quality and recognized education in health administration. Nurses looking to build on their existing experience may benefit from rn to bsn no clinical hours programs, which allow you to earn your degree without extra clinical requirements.

Those seeking advanced nursing degrees can consider accelerated or flexible doctor of nursing practice (DNP) programs. Options like the fastest dnp online program or even a 1 year dnp program online can help you achieve your career goals in less time.

These pathways offer numerous options for career growth in the healthcare field, whether you want to move into administration, advance your nursing practice, or pivot to other roles.

Best Scientists Citing Meletios A. Dimopoulos

Trending Scientists

Recently Published Articles